Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned an average recommendation of “Buy” from the sixteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $32.7692.

DNLI has been the subject of several research reports. UBS Group started coverage on Denali Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating for the company. JPMorgan Chase & Co. upped their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Morgan Stanley reiterated an “overweight” rating and set a $40.00 target price on shares of Denali Therapeutics in a report on Thursday, January 8th. Stifel Nicolaus set a $37.00 price target on shares of Denali Therapeutics in a report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $20.25 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The stock has a market cap of $2.97 billion, a price-to-earnings ratio of -6.96 and a beta of 1.05. The firm has a 50-day moving average of $17.88 and a two-hundred day moving average of $15.97. Denali Therapeutics has a 1 year low of $10.57 and a 1 year high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.02. During the same quarter in the prior year, the company posted ($0.63) EPS. The firm’s revenue was up .0% on a year-over-year basis. On average, research analysts forecast that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. lifted its position in shares of Denali Therapeutics by 31.8% during the fourth quarter. Assetmark Inc. now owns 5,187 shares of the company’s stock valued at $86,000 after buying an additional 1,250 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of Denali Therapeutics by 6.2% during the 4th quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock worth $203,253,000 after acquiring an additional 719,304 shares in the last quarter. Capricorn Fund Managers Ltd bought a new position in shares of Denali Therapeutics during the 4th quarter worth approximately $1,027,000. Aberdeen Group plc lifted its position in Denali Therapeutics by 82.6% during the fourth quarter. Aberdeen Group plc now owns 2,032,967 shares of the company’s stock valued at $33,564,000 after acquiring an additional 919,381 shares during the last quarter. Finally, Clarius Group LLC boosted its stake in Denali Therapeutics by 2.6% in the fourth quarter. Clarius Group LLC now owns 368,995 shares of the company’s stock valued at $6,092,000 after acquiring an additional 9,250 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.